Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Provenge Followed by Docetaxel in mCRPC
NCT02793219Phase 2Withdrawn
- Sponsor
- UTHealth Houston
- Start
- Dec 2016
- Primary completion
- Jul 2018
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC), sponsored by UTHealth Houston. Primary endpoints: Cytokine Activity at 18 months, T-cell Proliferation at 18 months and 3 more. Planned start Dec 2016; status: withdrawn.
02
Drugs
sipuleucel-T
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02793219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02793219.